Figure 2.

Modeling of cardiovascular genetic diseases using human iPSC platforms

(1) Disease variants can be modeled in vitro by reprogramming of iPSCs from the somatic cells of patients or healthy controls. Generation of iPSCs maintains the genetic integrity of disease, such as single-nucleotide variants, directly from patients; otherwise, they can be induced using genome editing on healthy control iPSCs. (2) Protocols for the differentiation of iPSCs into specialized cell types such as iPSC-CMs, iPSC-derived cardiac fibroblasts, iPSC-derived smooth muscle cells, iPSC-derived endothelial cells, and iPSC-derived cardiac pericytes are used to assess phenotypes in a dish, (3) providing disease modeling of diverse genetic cardiovascular diseases. Created with Biorender.com.